BCL2L11 and cancer: Increased expression of Bim has correlated with increased sensitivity to GC-induced apoptosis [55, 56], dysregulation of its gene expression has been found in solid and hematopoietic malignances [57], where reduced expression correlated with increased disease risk [58], and single nucleotide polymorphisms have been associated with impaired responsiveness to anticancer therapies [59–61].